New Drug Sales Help Boost Novartis Q1 Profit

The company said Thursday that its net profit of nearly $2.97 billion, which was up from $2.42 billion in the same period last year, was helped by sales growth from some of its newest product launches, such as Gilenya for multiple sclerosis and Afinitor for cancer. The company also noted that the strong sales were reinforced by asthma treatment Xolair gaining approval in the European Union and United States and meningitis B vaccine Bexsero being recommended in the U.K.

Topics:  afinitor   xolair   european union   united states   bexsero   u.k    u.s growth   china   sales   profit   gaining   helped   billion   company   
BING NEWS:
  • CAS Q1 sales down but profit up
    China Automotive Systems, the power steering components and systems supplier, said Q1 sales were down 2% to US$139.4m, gross profit increased 11.6% to $24.1m with a gross margin of 17.3% (versus 15.2% ...
    05/15/2024 - 12:00 am | View Link
  • Hemp-Focused CV Sciences Reports Steady Q1 Revenue Amid Operational Hurdles And Acquisition Of Nutraceuticals Manufacturer
    CV Sciences reports a slight Q1 revenue drop and acquires Elevated Softgels, aiming for strategic growth and enhanced production.
    05/14/2024 - 6:40 am | View Link
  • Biosimilars Boosts Sandoz Q1 Sales; Backs Annual Sales Outlook
    Biosimilars posted sales of $623 million, compared with $516 million in 2023. This reflects This strong double-digit growth reflects the ongoing launch of Hyrimoz high-concentration formulation, the ...
    05/6/2024 - 6:55 pm | View Link
  • Health News Roundup: Novartis to buy radiology drug specialist Mariana for $1 billion; Amgen first-quarter profit dips 1%, revenue rises 22% and more
    Zimmer's results extend a strong quarter for medical device makers, including peer Stryker Corp which raised its annual profit outlook betting on steady demand for its hip and knee implants. Novo ...
    05/2/2024 - 9:59 am | View Link
  • Novo Nordisk aims for market domination, boasts $1.5bn obesity sales in Q1
    Novo Nordisk noted a 22% boost in sales owing to increased sales of GLP-1 agonists and other obesity products.
    05/2/2024 - 8:30 am | View Link
  • More

 

Welcome to Wopular!

Welcome to Wopular

Wopular is an online newspaper rack, giving you a summary view of the top headlines from the top news sites.

Senh Duong (Founder)
Wopular, MWB, RottenTomatoes

Subscribe to Wopular's RSS Fan Wopular on Facebook Follow Wopular on Twitter Follow Wopular on Google Plus

MoviesWithButter : Our Sister Site

More Business News